MedTrace Logo

A Trial for Patients With Advanced/Recurrent Cervical Cancer

NCT00190983 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2009-11-20

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.

Conditions

  • Cervical Intraepithelial Neoplasia
  • Uterine Neoplasms
  • Genital Neoplasms, Female

Interventions

DRUG

Pemetrexed

Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.

Sponsors & Collaborators

Principal Investigators

  • David Miller, MD · Gynecologic Oncology Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00190983 on ClinicalTrials.gov